Silenseed Ltd. is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and a specific delivery system designed to effectively penetrate and treat malignant solid tumors: the LODER™ (LOcal Drug EluteR).